These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29319282)

  • 1. The risk of melanoma in patients treated with anti-TNFα: does it exist?
    Bardazzi F; Raone B; Sechi A; Patrizi A; Magnano M
    G Ital Dermatol Venereol; 2018 Feb; 153(1):119-120. PubMed ID: 29319282
    [No Abstract]   [Full Text] [Related]  

  • 2. Psoriasis: targeting therapy towards the inflammatory cascade.
    Miteva M
    Am J Clin Dermatol; 2010; 11 Suppl 1():11-3. PubMed ID: 20586499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of melanoma and hematologic cancers in patients with psoriasis.
    Reddy SP; Martires K; Wu JJ
    J Am Acad Dermatol; 2017 Apr; 76(4):639-647.e2. PubMed ID: 27876302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
    Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G
    Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long term treatment of psoriasis with TNF-alpha antagonists. Occurrence of malignant melanoma].
    Kowalzick L; Eickenscheidt L; Komar M; Schaarschmidt E
    Hautarzt; 2009 Aug; 60(8):655-7. PubMed ID: 19280165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
    Asgari MM; Ray GT; Geier JL; Quesenberry CP
    J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. Foreword.
    Gottlieb AB
    Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S3-4. PubMed ID: 24777570
    [No Abstract]   [Full Text] [Related]  

  • 8. [Up-date on the use of infliximab in dermatology. Introduction].
    Sánchez-Carazo J
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():1. PubMed ID: 19080984
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination therapy of biologics with traditional agents in psoriasis.
    Guenther LC
    Skin Therapy Lett; 2011 Jun; 16(6):1-3. PubMed ID: 21833461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tumor necrosis factor α inhibitors extend beyond psoriasis: insulin sensitivity in psoriasis patients with type 2 diabetes mellitus.
    Al-Mutairi N; Shabaan D
    Cutis; 2016 Mar; 97(3):235-41. PubMed ID: 27023086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with tumor necrosis factor inhibitors in psoriasis treatment.
    Famenini S; Wu JJ
    Cutis; 2013 Sep; 92(3):140-7. PubMed ID: 24153143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous malignancies during treatment with efalizumab and infliximab: When temporal relationship does not mean causality.
    Di Lernia V; Ricci C
    J Dermatolog Treat; 2011 Aug; 22(4):229-32. PubMed ID: 20666674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Body-weight changes in psoriatic patients on systemic treatment].
    Forien M; Mahé E; Sin C; Marchal A; Sigal ML
    Ann Dermatol Venereol; 2012 Oct; 139(10):649-51. PubMed ID: 23122380
    [No Abstract]   [Full Text] [Related]  

  • 14. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.
    Yanaba K; Umezawa Y; Honda H; Sato R; Chiba M; Kikuchi S; Asahina A; Nakagawa H
    J Dermatol; 2016 Apr; 43(4):443-4. PubMed ID: 26662275
    [No Abstract]   [Full Text] [Related]  

  • 15. Autoimmunity by anti-tumour necrosis factor-alpha agents: the role of traditional therapies.
    Antoniou C; Moustou AE; Vergou T; Stratigos A; Kalambokas A; Katsambas AD
    J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):356-7. PubMed ID: 19686257
    [No Abstract]   [Full Text] [Related]  

  • 16. Data on the safety of psoriasis therapies.
    Leonardi CL
    Semin Cutan Med Surg; 2014 Jun; 33(4 Suppl):S73-5. PubMed ID: 25268600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early videocapillaroscopic changes of the psoriatic skin after anti-tumour necrosis factor alpha treatment.
    De Angelis R; Gasparini S; Bugatti L; Filosa G
    Dermatology; 2005; 210(3):241-3. PubMed ID: 15785057
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-tuberculous mycobacterial infections in psoriasis patients treated with biologics.
    Choi YM; Adelzadeh L; Wu JJ
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e99-e101. PubMed ID: 26388307
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors.
    Famenini S; Sako EY; Wu JJ
    Am J Clin Dermatol; 2014 Feb; 15(1):45-50. PubMed ID: 24281789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy for psoriasis.
    Lee M; Kalb RE
    Dermatol Nurs; 2008 Apr; 20(2):105-11; quiz 112. PubMed ID: 18549125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.